These Studies Were Published.  The Question is – Did Anyone Act on Them?

Jun 25, 2026

Most of us who work in surgical wound care have seen a lot of studies come and go. Some change practice, but most don’t. Not because the evidence wasn’t there but because the supply chain, the contract, and the committee cycle moved faster than the literature. 

These three studies deserve a second look. The evidence was consistent, the patient populations were large, and the question of having negative pressure setting choices should at least be on the table.

Three peer-reviewed studies. 
Thousands of patients. 
In fact, 38,500+ patients. 
Real-world data and randomized trials. 

All of them pointing in the same direction – and yet, in most OR’s nothing changed. 

Why? Because in most hospital systems, the device on the shelf was chosen by a contract negotiated before these data findings existed.  

The patients end up with whatever device the GPO negotiated, which is not necessarily the one the evidence supports.

Here is what 3 published studies found:

Across a retrospective US claims database analysis of more than 22,000 orthopedic and cardiovascular patients, the authors reported:

“The -80 mm/Hg device was associated with significantly lower HCRU (healthcare resource use) and likelihood of dehiscence after orthopedic and cardiovascular surgery versus the -125 mm/Hg device and there were no differences in other SSC’s.” (Bashyal RK et al., Journal of Wound Care, 2025)

In a separate retrospective of US claims database study directly comparing to single use NPWT devices after cesarean delivery with 5,332 patients in each group (10,600+ patients) the findings were:

“Overall SSI, superficial SSI, dehiscence, seroma and costs were significantly lower with the -80 mm/Hg device compared with the -125 mm/Hg device (P < .05). No differences between the 2 devices were observed for hematoma, deep SSI, and LOS (P > .05).” (Wilkins AL et al., Wounds, 2025)

Another is a systemic review and meta-analysis of 11 randomized controlled trials involving 5,847 cesarean patients:

“A statistically significant Improvement in the composite SSI (OR 0.69; 95% Cl: 0.54 – 0.89) and superficial SSI (OR: 0.66; 95% Cl: 0.50 – 0.86) outcomes were observed with the -80 mm/Hg device, compared with the standard dressings.  The same effect on SSI outcomes was not observed with the -125 mm/Hg device.” (Goldman T et al., American Journal of Perinatology, 2023)

Three studies. Different patient populations. Same signal. 

So again, if the evidence is shifting, and your choices are not, it may be time to ask why.

It’s important to mention, not every clinician has seen these studies. And for those who have, the truth is that a lot of people in this field may feel constrained by what is stocked in their institution. At some point someone has to bring it to the table, in a value analysis meeting, a surgical committee, or even just having some open conversations with other clinicians.

If you are a surgeon, a wound care specialist, or someone who sits on one of the value analysis committees, this is exactly the kind of evidence that belongs in that room. We truly want your perspective. Has your institution evaluated pressure level differences when selecting your single-use NPWT device, or did the contract make that decision?

If the evidence is shifting, and your options are not, is it time to ask why?

References:

Bashyal RK et al., Journal of Wound Care, 2025
Wilkins AL et al., Wounds, 2025 
Goldman T et al., American Journal of Perinatology, 2023